A recent study profiling the anti-tumor effects of 16 different PI3K/AKT/mTOR pathway inhibitors in combination with paclitaxel in a panel of ovarian cancer cell lines and primary ovarian tumor cells covering the four main subtypes of EOC, found that the dual PI3K/mTOR inhibitor GSK458 in particular was a potent inhibitor of proliferation and cell migration in vitro, and was able to reduce tumor growth and metastasis in both SKOV3 xenograft and PDCX models in vivo[130]. Here, PIK3CA is linked to ovarian cancer.